NT5E and head and neck squamous cell carcinoma: Our results suggest that HNSCC patients with high CD73 expression may be relatively refractory to immunotherapy, and in the metastatic urothelial carcinoma cohort, CD73 expression was indeed lower in immune-responsive patients.